Pet nutrition and tech companies raised new funding across four rounds

Four pet-adjacent companies closed funding rounds, with capital earmarked for manufacturing facilities, alternative protein production, healthcare distribution infrastructure, and black soldier fly genetics.

The capital and where it went

Mumbai-based pet food company Lickicious raised $1.9 million in a round combining equity and institutional debt, led by early-stage venture capital firm Prath Ventures with participation from ISV Capital. The company plans to use a significant portion of the capital to establish a 60,000-square-foot manufacturing and distribution facility. Lickicious, founded in 2023 as the digital-first brand of Indian pet food company Nuvexo Wellness, said it aims to reach $10 million in annual revenue as its next milestone and build one of India's top three pet food companies over the next decade.

Belgian biotechnology company MAASH raised a $14.1 million package comprising $6.8 million in equity from five new investors, Ambra Capital, InvestPro, Bpifrance, Nordzucker, and Tereos, plus $5 million in support from public investment bank Bpifrance and a $2.3 million loan. MAASH is scaling LoCylia, its fermentation-derived mycoprotein ingredient designed for blended meat and pet food applications. In pet food, LoCylia acts as an alternative to fishmeal, soy, and legumes. The funding will support the launch of a demonstration plant in Carling-Saint-Avold, France, and prepare the company for industrial-scale production.

Indian healthcare supply chain startup DocPharma closed a $2 million pre-Series A round led by investment advisory firm Equentis, with participation from existing investors 100Unicorns, Vinners, and strategic angel investors. The company will use the capital to expand its healthcare fulfillment network from 12 to over 50 cities and add 100 new licensed dark stores, retail-style warehouses and distribution centers, across the country. DocPharma currently works with more than 30 healthcare and wellness platforms, including e-pharmacies, hospitals, health insurers, corporate wellness companies, and direct-to-consumer brands, some of which operate in the pet care sector. Its network stocks over 40,000 SKUs and enables partner platforms to deliver medicines and healthcare products within 30 minutes. To date, the startup has fulfilled more than 800,000 orders.

Edinburgh-based black soldier fly genetics company Beta Bugs secured $1.1 million to accelerate commercialization of its HiPer-Fly genetics and expand its international customer base and network of strategic partners. The investment, led by angel investment syndicate TRICAPITAL Angels and supported by economic development agency Scottish Enterprise, will help the company meet demand from the commercial insect farming industry for higher-performing and more consistent black soldier fly genetics. HiPer-Fly was developed through selective breeding to improve growth, yield, survival, and production consistency. Beta Bugs partnered with Israeli agritech firm FreezeM to supply the genetics using PauseM, a patent-pending biotechnology product that pauses the life cycle of newly hatched black soldier fly larvae for up to 21 days, supporting commercial rollout across Europe.

What the capital deployment pattern shows

Three of the four rounds fund physical infrastructure, manufacturing facilities, distribution centers, demonstration plants, rather than marketing or customer acquisition. Lickicious is building a 60,000-square-foot facility. MAASH is funding a demonstration plant in France to prove industrial-scale production works. DocPharma is adding 100 dark stores to cut delivery windows from hours to minutes.

The fourth round, Beta Bugs' $1.1 million, funds genetics rather than farming capacity, but it addresses production as well. Black soldier fly larvae are an ingredient input for pet food formulations, and Beta Bugs is selling the genetics to insect farmers who supply protein to pet food manufacturers. The capital goes toward breeding programs and commercial relationships, not consumer-facing distribution.

If your category depends on alternative protein or you're watching the India market, subscribe to PetRetailNews.

The retail angle these rounds do not answer

None of the four companies named a retail partner, a shelf placement, or a distribution deal in the announcements. Lickicious said it plans to explore new sales channels and broaden its national reach, but did not specify whether that means independent pet retail, regional chains, or e-commerce expansion. MAASH is a B2B ingredient supplier, not a finished-goods brand, so its path to shelf runs through the pet food manufacturers it supplies. DocPharma works with direct-to-consumer pet care brands, but the company did not name them or say whether any of those brands are pursuing brick-and-mortar retail. Beta Bugs sells to insect farmers, who sell to ingredient processors, who sell to pet food manufacturers, three steps removed from a store shelf.

The capital these companies raised funds the infrastructure that would let them scale if retail demand materializes, but the announcements do not prove that demand exists yet. A 60,000-square-foot facility and a demonstration plant are responses to anticipated orders, not current ones.

Our read on the manufacturing-first pattern

The infrastructure focus suggests that investors believe the constraint in alternative protein, India pet food, and healthcare logistics is production capacity, not consumer willingness to buy. If the constraint is on the supply side, then the brands and ingredient suppliers that build capacity now win the contracts when a retailer or a manufacturer wants to scale a launch.

Production capacity without confirmed retail demand is overhead. A facility that runs below capacity because the retail partnerships did not materialize costs more than no facility at all. MAASH's demonstration plant in France proves industrial-scale production is possible, but it does not prove a pet food manufacturer will reformulate around mycoprotein at the volume the plant requires to break even.

For a buyer or a store owner, watch whether any of these funded companies announce a retail partnership or a co-manufacturing deal in the next six months. If they do, the infrastructure they are building now becomes relevant to your shelf. If they do not, the funding rounds were placed on a future that has not arrived yet.

← Back to the Newsdesk